Mucopolysaccharidosis (MPS) type-IH is a lysosomal storage disease that results from mutations
Severe mucopolysaccharidosis type I, Hurler's syndrome (MPS-IH), is a lysosomal storage disease due to mutations in the IDUA gene resulting in decreased/absent alpha-L-iduronidase activity. The consequent accumulation of the glycosaminoglycans (GAGs), heparan sulfate (HS) and dermatan sulfate (DS), in tissues results in a number of clinical features including hepatosplenomegaly, progressive cognitive impairment, cardiovascular complications, and joint and bone abnormalities (dysostosis multiplex) 1 . Currently, exogenous enzyme replacement using recombinant alpha-L-iduronidase is available to patients with MPS-I, although it does not cross the blood brain barrier in significant amounts 2 . To achieve continuous enzyme delivery as well as provide a cerebral source of cells expressing alpha-L-iduronidase (presumed to be microglia), hematopoietic cell transplant (HCT) is used as standard of care for patients with Hurler syndrome 3, 4 . HCT leads to an increase in IDUA enzyme activity and concomitant reductions in substrate levels as well as stabilization of neurodegeneration [5] [6] [7] . HCT does not arrest the progression of joint and bone disease [8] [9] [10] [11] , nor does it reverse the characteristic changes in the heart valves 12, 13 . These observations suggest that GAG accumulation is not the sole mediator of disease-related complications in MPS-IH 14 . Recent work in rodent models supports that co-existent immune and microglial inflammatory processes contribute to the pathology of several MPS diseases with demonstrating several key inflammatory cytokines including IL-6, IL-8, MIP1-beta, MIP1-alpha, and MCP-1 [15] [16] [17] . As mentioned, prior to the development of HCT, children with MPS-IH were observed to develop progressive, debilitating developmental and cognitive deterioration 7 . While there have been several descriptions of various plasma biomarkers for MPS-IH 5, [18] [19] [20] [21] , no study has systematically evaluated the cerebrospinal fluid (CSF). Here, we document for the first time, the characteristics of MPS-IH CSF with a focus on inflammatory cytokines.
Results
We performed a lumbar puncture and CSF analysis on 25 consecutive patients with MPS-IH with a median age of 11.2 months. Nearly all CSF was free from erythrocytes or white blood cells. As shown in Fig. 1 Using the Sensi-Pro ® assay, we measured NREs characteristic for MPS-IH, I0S0 and I0S6, and also determined total HS concentration 19 . We found a significant elevation in I0S0 and I0S6 with an average of 56.3 and 249.1 ng/mL respectively (with normal values of < 15 and < 30 ng/mL, respectively 19 ) as shown in Fig. 2 . Total HS was also significantly elevated with an average of 278.1 ± 108.2 ng/mL (normal < 120 ng/mL) (Fig. 2) .
We also evaluated HCII-T (heparin cofactor II-thrombin) complex, a previously described biomarker of lysosomal storage diseases including MPS-IH 18 . We found a significant elevation with a mean level of 4.5 ± 1.4 ng/mL of HCII-T complex (reference range: < 0.25 ng/mL) (Fig. 3) .
We found six inflammatory markers to be significantly elevated in children with MPS-IH when compared to controls: monocyte chemoattractant protein-1 (MCP-1) (mean 811 vs 328 pg/mL, p < 0.001), stromal cell-derived factor-1a (SDF-1a) (784 vs 200 pg/mL, p < 0.0001), interleukin-1 receptor antagonist (IL-Ra) (62 vs 6 pg/mL, p < 0.0001), macrophage inflammatory protein 1-beta (MIP-1b) (13.1 vs 3.3 pg/mL, p = 0.04), interleukin-8 (IL-8) (39 vs 17 pg/mL, p < 0.0001), and vascular endothelial growth factor (VEGF) (5.1 vs 0.1 pg/mL, p < 0.0001) as shown Fig. 4 .
Discussion
We report potential CSF biomarkers for patients with MPS-IH. These may be important to consider as further therapies are being developed either through immunomodulation, hematopoietic stem cell transplant, new forms of enzyme therapy and other interventions. These biomarkers may serve as indicators to which we can compare the effectiveness of new interventions. In addition, they may prove useful as a means of identifying future phenotypes in children diagnosed through newborn screening that display novel or poorly characterized genotypes. We found the mean CSF OP was higher in children with MPS-IH than what is considered "typical" for healthy children, which is <20 cm H 2 24 , our patients all had strict end-tidal CO 2 monitored and maintained from 25-40 mm Hg. Classically, elevated OP is associated with intracranial processes such as infection (bacterial, viral, or fungal meningitis), subarachnoid hemorrhage, pseudotumor cerebri, or any communicating hydrocephalus. Our data suggest that GAG accumulation and perhaps subacute neuroinflammation may contribute to an increase in OP. We should note that none of our patients has evidence of papilledema suggesting that their increased OP was not severe enough to affect the optic nerve head.
An inflammatory process has been implicated as a pathological contributor to MPS disease 21 , with specific contributions to skeletal manifestations. Simonaro et al. previously found TNF-alpha to be elevated in MPS VII mice and treatment of MPS VI affected rats with Infliximab, an antibody targeted to TNF-alpha, significantly reduced joint disease 15 . Additionally, the anti-inflammatory compound, pentosan polysulfate, has been shown to reduce inflammation associated bone pathology in a rat model of MPS VII and is now entering clinical trials in MPS patients 25 .
In this study, we demonstrate for the first time that markers of inflammation are manifest in the CSF of MPS patients. Our data is consistent with what others have shown in the brain of MPS animal models. For example, Wilkinson et al. showed significantly high levels of MCP-1 in the brain of MPSI, MPSIIIA, and MPSIIIB mice 17 . The links between the immune system of MPS pathology as it relates to the neurological and skeletal system is becoming more appreciated 26 . It is doubtful that a single cytokine or inflammatory factor is responsible for MPS pathology, as many of the inflammatory proteins exist in a "cascade" of factors where initiation of inflammation is followed by waves of chemokine secretion and recruitment of immune cells. Several of the elevated factors we show here are also associated with other neuroinflammatory conditions, including MCP-1 and MIP-1b which are elevated in patients with multiple sclerosis, while MCP-1, MIP-1b, IL-8, and SDF-1a are elevated in stroke victims 27 . Whether the CSF inflammatory mediators are due to GAG accumulation or another process is not known. There are very few reports of CSF GAG evaluation in patients afflicted with a mucopolysaccharidosis diagnosis [28] [29] [30] , and we believe this is the first study to evaluate non-reduced ends (NREs) and HS levels in the CSF of MPS-IH patients. Clinical trials investigating the use of anti-inflammatory agents are being developed in MPS-I and other MPS subtypes for the purpose of ameliorating joint and bone disease 25 . Novel attempts at targeting the CSF with recombinant viral vectors delivering the missing enzyme are being developed in several MPS diseases as well [31] [32] [33] [34] [35] . Commonly, glycan-based markers are used to show efficacy for these various strategies 36 . Based on our CSF findings, it may also be important to collect and assess both CSF GAG and inflammatory markers as new clinical trials evolve, since reducing inflammation will likely coincide with an impact on neurological processes and perhaps skeletal disease as noted above. Control patients for biomarker analyses (n = 25, median age 6.8 years, range 4-17 years) were those undergoing intrathecal chemotherapy for a prior diagnosis of acute lymphoblastic leukemia, at least 3 months into maintenance therapy, and without a CSF leukemia diagnosis. In controls, CSF was withdrawn just prior to administration of the intrathecal chemotherapy and cytokine concentrations determined by ELISA. Unavailability of "healthy" controls due to the risks inherent to attaining CSF from "healthy" children established these patients as the most appropriate control group available and has been previously published by our group and others [37] [38] [39] . This study was approved by the Committee on the Use of Human Subjects in Research at the University of Minnesota, and all experiments were performed in accordance with relevant guidelines and regulations by the Committees on the Use of Human Subjects in Research at the University of Minnesota. Informed written consent was obtained for all patient samples from the parents or guardians on behalf of the child participants. Table 1 . SDF-1alpha was measured by sandwich ELISA (R&D Systems, Minneapolis, MN).
Heparin cofactor II-thrombin (HCII-T).
HCII-T complex was determined by ELISA, following the manufacturer's instruction (#MBS904277, Mybiosource, San Diego, CA).
Non-Reducing Ends (NREs) and total HS. The CSF NREs (I0S0 and I0S6) and total HS (calculated from the addition of the internal disaccharides, D0A0 + D0S0) were determined using the Sensi-Pro ® assay as previously described 19 .
Statistical methods. Cytokine measurements were made in duplicate and the average of the two values was used to determine concentration using standard curves generated with the relevant recombinant human proteins provided with the commercial kits. Means for the MPS-IH and control groups were calculated and subjected to a two-tailed Student's t-test to compute a p-value.
